| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2000;120:370-378
© 2000 The American Association for Thoracic Surgery
Cardiopulmonary support and physiology |
From the BHF Units of Cardiothoracic Surgerya and Cardiovascular Medicine,b National Heart and Lung Institute, and the Department of Haematology,c Hammersmith Hospital, Imperial College School of Medicine, London, United Kingdom.
Supported by grants from the British Heart Foundation and Glaxo-Wellcome PLC.
Address for reprints: R. Clive Landis, PhD, BHF Cardiovascular Medicine Unit, National Heart and Lung Institute, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom (E-mail: r.landis{at}ic.ac.uk ).
Background: Despite aprotinin being in widespread clinical use to prevent bleeding during cardiac surgery, there remains concern that such a powerful hemostatic agent may also be prothrombotic, particularly in relation to coronary vein graft occlusion. The major thrombin receptor on platelets, protease-activated receptor 1 (PAR1) requires proteolytic cleavage to transmit activating signals. Here we have investigated the effect of aprotinin on thrombin-induced PAR1 activation of platelets.
Methods and results: Proteolysis-dependent and -independent responses of washed platelets were studied in vitro. Platelet aggregation induced by trypsin was dependent on PAR1 (inhibited by the PAR1-specific antagonist peptide, FLLRN) and was completely blocked by aprotinin at doses more than 100 KIU/mL. Aggregation in response to thrombin, 1 nmol/L, was predominantly mediated through PAR1 and was inhibited 42.6% to 86.6% (P < .05-.001) by pharmacologic doses of aprotinin (50-160 KIU/mL). Aprotinin did not inhibit the nonproteolytic agonists collagen, epinephrine, adenosine diphosphate, or phorbol 12-myristate 13-acetate. Furthermore, blockade of the thrombin response by aprotinin did not prevent subsequent platelet aggregation through collagen or epinephrine. Experiments with intraplatelet Ca2+ fluxes, which provided an earlier measure of platelet activation, placed the effect of aprotinin proximal to the PAR1 activation event. Since aprotinin did not inhibit platelet responses to the nonproteolytic PAR1 agonist peptide, SFLLRN, this implied that aprotinin acted by preventing PAR1 receptor cleavage by thrombin.
Conclusions: Aprotinin inhibits thrombin-induced platelet activation by preventing proteolysis of the PAR1 receptor. These findings argue against aprotinin being prothrombotic and suggest instead that aprotinin may have significant antithrombotic effects.
Related Article
J. Thorac. Cardiovasc. Surg. 2000 120: 361-369.
This article has been cited by other articles:
|
|
 |
|
  A. M. Mengistu, K. D. Rohm, J. Boldt, J. Mayer, S. W. Suttner, and S. N. Piper The Influence of Aprotinin and Tranexamic Acid on Platelet Function and Postoperative Blood Loss in Cardiac Surgery Anesth. Analg., August 1, 2008; 107(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Iwata, O. Nicole, T. Okamura, D. Zurakowski, and R. A. Jonas Aprotinin confers neuroprotection by reducing excitotoxic cell death J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 573 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Mossad, S. Machado, and J. Apostolakis Bleeding following deep hypothermia and circulatory arrest in children. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46. [Abstract] [PDF]
|
|
|
|
|
|
V. Anttila, I. Hagino, Y. Iwata, B. A. Mettler, H. G.W. Lidov, D. Zurakowski, and R. A. Jonas Aprotinin improves cerebral protection: Evidence from a survival porcine model J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 948 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. S. Day, R. C. Landis, and K. M. Taylor Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2006; 10(2): 132 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Jaggers and J. H. Lawson Coagulopathy and Inflammation in Neonatal Heart Surgery: Mechanisms and Strategies Ann. Thorac. Surg., June 1, 2006; 81(6): S2360 - S2366. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Weerasinghe, T. Athanasiou, P. Philippidis, J. Day, K. Mandal, O. Warren, J. Anderson, and K. Taylor Platelet-monocyte pro-coagulant interactions in on-pump coronary surgery Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R.S. Day, D. O. Haskard, K. M. Taylor, and R. C. Landis Effect of Aprotinin and Recombinant Variants on Platelet Protease-Activated Receptor 1 Activation Ann. Thorac. Surg., February 1, 2006; 81(2): 619 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R.S. Day, K. M. Taylor, E. A. Lidington, J. C. Mason, D. O. Haskard, A. M. Randi, and R. C. Landis Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1 J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hess Jr. Systemic inflammatory response to coronary artery bypass graft surgery Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S6 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S15 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Khan, C. Bianchi, E. Araujo, P. Voisine, S.-H. Xu, J. Feng, J. Li, and F. W. Sellke Aprotinin Preserves Cellular Junctions and Reduces Myocardial Edema After Regional Ischemia and Cardioplegic Arrest Circulation, August 30, 2005; 112(9_suppl): I-196 - I-201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van der Linden, G. Lindvall, and U. Sartipy Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial Circulation, August 30, 2005; 112(9_suppl): I-276 - I-280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, S. R. Mehta, and S. F. Aranki Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery Ann. Thorac. Surg., August 1, 2005; 80(2): 768 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Akowuah, V. Shrivastava, B. Jamnadas, D. Hopkinson, P. Sarkar, R. Storey, P. Braidley, and G. Cooper Comparison of Two Strategies for the Management of Antiplatelet Therapy During Urgent Surgery Ann. Thorac. Surg., July 1, 2005; 80(1): 149 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Khan, C. Bianchi, P. Voisine, J. Sandmeyer, J. Feng, and F. W. Sellke Aprotinin Inhibits Protease-Dependent Platelet Aggregation and Thrombosis Ann. Thorac. Surg., May 1, 2005; 79(5): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W.A. Chu, S. R. Wilson, R. J. Novick, L. W. Stitt, and M. A. Quantz Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery? Ann. Thorac. Surg., November 1, 2004; 78(5): 1536 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.R.S. Day, P.P. Punjabi, A.M. Randi, D.O. Haskard, R.C. Landis, and K.M. Taylor Clinical Inhibition of the Seven-Transmembrane Thrombin Receptor (PAR1) by Intravenous Aprotinin During Cardiothoracic Surgery Circulation, October 26, 2004; 110(17): 2597 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J R S Day, I S Malik, A Weerasinghe, M Poullis, I Nadra, D O Haskard, K M Taylor, and R C Landis Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention Heart, July 1, 2004; 90(7): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Chong, C. R. Hampton, and E. D. Verrier Microvascular Inflammatory Response in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 333 - 354. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Akowuah, V. Shrivastava, and G. Cooper Coronary artery bypass graft surgery in patients with recent exposure to clopidogrel and aspirin therapy J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1425 - 1426. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Frumento, C. M.N. O'Malley, and E. Bennett-Guerrero Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens Ann. Thorac. Surg., February 1, 2003; 75(2): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy Invited commentary Ann. Thorac. Surg., February 1, 2003; 75(2): 483 - 484. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy and K. A. Tanaka Inflammatory response to cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2003; 75(2): S715 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gourlay and G. Asimakopoulos Invited commentary Ann. Thorac. Surg., January 1, 2003; 75(1): 215 - 216. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis Aprotinin: Antithrombotic and Vasoactive Mechanisms of Action Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 307 - 312. [Abstract] [PDF]
|
|
|
|
|
|
L. Englberger, P. Markart, F.S. Eckstein, F.F. Immer, P.A. Berdat, and T.P. Carrel Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Q. Molenaar, R. J. Porte, M. G. Fitzsimons, and R. A. Peterfreund Aprotinin and Thromboembolism in Liver Transplantation: Is There Really a Causal Effect? * Response Anesth. Analg., May 1, 2002; 94(5): 1367 - 1368. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Stoica, M. Goddard, and S. R. Large The endothelium in clinical cardiac transplantation Ann. Thorac. Surg., March 1, 2002; 73(3): 1002 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Poullis, R C Landis, and K M Taylor Aprotinin: is it prothrombotic? Perfusion, September 1, 2001; 16(5): 401 - 409. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Landis and K. M. Taylor Aprotinin administration in the pericardial cavity does not prevent platelet activation J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 405 - 405. [Full Text] [PDF]
|
|
|
|
|
|
G. Asimakopoulos, E. A. Lidington, J. Mason, D. O. Haskard, K. M. Taylor, and R. C. Landis Effect of aprotinin on endothelial cell activation J. Thorac. Cardiovasc. Surg., July 1, 2001; 122(1): 123 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Mojcik and J. H. Levy Aprotinin and the systemic inflammatory response after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2001; 71(2): 745 - 754. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
